We hypothesised that NGF is produced by the bone microenvironment in response to secretion of inflammatory factors by MM cells, inducing central pain-related effects, and that adiponectin signalling may quell these changes in a manner not shared by traditional MM therapeutics. The gene discussed is NGF; the disease is Miyoshi myopathy.